Mereo Biopharma (MREO) Fundamental Analysis: Revenue, Earnings & Valuation

1.78 / 10

Underperform

Fundamental analysis rates MREO as Underperform with a 1.8/10 strength. Accounts receivable turnover and interest coverage are decent, yet fixed‑asset turnover, income‑tax ratio and PB‑ROE are weak. Revenue growth is high but overall financial health remains fragile.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score3/3

Weight66.25%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight3.52%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-3.76%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-3.73%

1M Return-0.65%

PB-ROE

Value5.04

Score0/3

Weight27.24%

1M Return3.80%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-8.47%

1M Return-1.54%

Fixed assets turnover ratio

Value0.73

Score1/3

Weight-6.98%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.20%

1M Return-0.73%

Cost of sales ratio (%)

Value26.60

Score2/3

Weight-4.13%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight34.26%

1M Return4.88%

Is MREO fundamentally strong?

MREO scores 1.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -82.21% ROE, 0.00% net margin, -1.34 P/E ratio, 1.38 P/B ratio, and 16.67% earnings growth, these metrics solidify its Underperform investment rating.